Skip to main content
. Author manuscript; available in PMC: 2013 Sep 18.
Published in final edited form as: In Vivo. 2013 Mar-Apr;27(2):177–187.

Figure 2.

Figure 2

Immunoreactivity to rat antiSFFVgp52 Env and goat antiMLV Gag (gammaretroviral) antibodies. A: Immunoreactivity to goat anti-Gag IgG pAb (Dylight488 bovine anti-goat IgG pAb secondary) in a duodenal biopsy of an ME case. B: Immunoreactivity to rat antiEnv IgG1κ mAb (rhodamine donkey anti-rat IgG pAb secondary) in a duodenal biopsy of an ME case. C: Overlay of images A and B (Bar represents 20 µm). D: Morphology of the immunoreactive cells of an ME case. E: Immunoreactivity to goat antiGag IgG pAb (Dylight488 bovine antigoat IgG pAb secondary) in a duodenal biopsy of a control. F: Immunoreactivity to rat anti-Env IgG1κ mAb (rhodamine donkey antirat IgG pAb secondary) in a duodenal biopsy of a control. G: Overlay of images E and F (Bar represents 20 µm). H: Morphology of the immunoreactive cells of a control. TOPO3 was used to indicate nucleus localization in all images.